Innoviva (INVA) Competitors

Alkermes (NASDAQ:ALKS) and Innoviva (NASDAQ:INVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, community ranking, profitability, earnings, risk, media sentiment, institutional ownership and valuation.

Does the media favor ALKS or INVA?

In the previous week, Alkermes had 20 more articles in the media than Innoviva. MarketBeat recorded 26 mentions for Alkermes and 6 mentions for Innoviva. Innoviva's average media sentiment score of 1.31 beat Alkermes' score of 0.73 indicating that Innoviva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Innoviva	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ALKS or INVA more profitable?

Alkermes has a net margin of 23.57% compared to Innoviva's net margin of 18.31%. Alkermes' return on equity of 30.80% beat Innoviva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	23.57%	30.80%	19.09%
Innoviva	18.31%	20.84%	11.38%

Which has more risk & volatility, ALKS or INVA?

Alkermes has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Do analysts recommend ALKS or INVA?

Alkermes presently has a consensus price target of $38.33, indicating a potential upside of 20.62%. Innoviva has a consensus price target of $55.00, indicating a potential upside of 193.80%. Given Innoviva's stronger consensus rating and higher probable upside, analysts plainly believe Innoviva is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.67
Innoviva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer ALKS or INVA?

Alkermes received 397 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 70.16% of users gave Alkermes an outperform vote while only 57.52% of users gave Innoviva an outperform vote.

Company	Underperform	Outperform
Alkermes	Outperform Votes 703 70.16%	Underperform Votes 299 29.84%
Innoviva	Outperform Votes 306 57.52%	Underperform Votes 226 42.48%

Do insiders and institutionals hold more shares of ALKS or INVA?

95.2% of Alkermes shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 4.4% of Alkermes shares are held by insiders. Comparatively, 2.3% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, ALKS or INVA?

Alkermes has higher revenue and earnings than Innoviva. Alkermes is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.56B	3.36	$367.07M	$2.17	14.65
Innoviva	$358.71M	3.27	$179.72M	$0.19	98.53

Summary

Alkermes beats Innoviva on 12 of the 18 factors compared between the two stocks.